Cannabinoid receptor 2 deficiency results in reduced neuroinflammation in an Alzheimer's disease mouse model
- 1 February 2015
- journal article
- Published by Elsevier in Neurobiology of Aging
- Vol. 36 (2) , 710-719
Abstract
No abstract availableKeywords
Funding Information
- Deutsche Forschungsgemeinschaft (FOR926 SP10, FOR926 SP6)
This publication has 21 references indexed in Scilit:
- Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 miceJournal of Neuroinflammation, 2012
- Cannabidiol and Other Cannabinoids Reduce Microglial Activation In Vitro and In Vivo: Relevance to Alzheimer’s DiseaseMolecular Pharmacology, 2011
- Is lipid signaling through cannabinoid 2 receptors part of a protective system?Progress in Lipid Research, 2011
- Neuroinflammatory processes in Alzheimer’s diseaseJournal of Neural Transmission, 2010
- Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: Effects of oligomeric and fibrillar amyloid-βJournal of Neuroimmunology, 2009
- Dynamics of the Microglial/Amyloid Interaction Indicate a Role in Plaque MaintenanceThe Journal of Neuroscience, 2008
- Cannabinoid CB2 receptors in human brain inflammationBritish Journal of Pharmacology, 2008
- Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial ActivationJournal of Neuroscience, 2005
- High‐yield isolation of murine microglia by mild trypsinizationGlia, 2003
- Correlation between cognitive deficits and Aβ deposits in transgenic APP+PS1 miceNeurobiology of Aging, 2001